Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Immunic Q2 EPS $(0.21) Beats $(0.24) Estimate, Exits Quarter With Cash & Equivalents Worth $79.698M

Author: Benzinga Newsdesk | August 08, 2024 06:35am
Immunic (NASDAQ:IMUX) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.23) by 8.7 percent. This is a 61.11 percent increase over losses of $(0.54) per share from the same period last year.

Posted In: IMUX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist